This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected
by Zacks Equity Research
IntelliPharmaCeutics International Inc. (IPCI) reported loss of 7 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 9 cents per share.
Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops
by Arpita Dutt
Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.
5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now
by Zacks Equity Research
Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
by Zacks Equity Research
We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.
Dow 30 Stock Roundup: Boeing Bags Air Force Orders, DuPont to Sell Part of Crop Protection Biz
by Swarup Gupta
The Dow experienced a relatively quiet week as investors eagerly awaited the outcome of the Trump Xi meeting.
AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.
Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that its supplemental new drug application (sNDA) to convert accelerated approval for Ibrance to regular approval has been approved by the FDA.
Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
by Arpita Dutt
Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA
by Zacks Equity Research
AstraZeneca plc (AZN) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation
Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula
by Zacks Equity Research
TESARO, Inc. (TSRO) recently announced that the FDA has approved its oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor Zejula for ovarian cancer in women.
AstraZeneca's Lung Cancer Drug Tagrisso Approved in China
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.
AstraZeneca Stock Rising in '17: What's Working in its Favor?
by Zacks Equity Research
Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.
Infinity Pharma Focuses on Cancer Drug: Competition Looms
by Zacks Equity Research
We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
by Zacks Equity Research
London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.
AstraZeneca (AZN): Should Value Investors Pick this Stock?
by Zacks Equity Research
Is AstraZeneca a great pick from the value investor's perspective right now? Read on to know more.
Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
by Arpita Dutt
Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.
Inovio (INO) Q4 Loss Wider than Expected; Shares Decline
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) reported a loss of 36 cents for the fourth quarter of 2016.
AstraZeneca's Cancer Drug Lynparza Positive in Phase III
by Zacks Equity Research
AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.
How Incyte Stock Became a Bull Market Star for Biotech Investors
by Arpita Dutt
Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.
Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA
by Zacks Equity Research
Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.
The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi
Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug
by Arpita Dutt
Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
by Arpita Dutt
Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.